Allarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough – QNT Press Release

NY City, New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) — Diamond in the Rough

Click here for full length version of article.

Allarity TherapeuticsInc. (NASDAQ:ALLR) is a clinical stage oncology therapeutics company founded in Denmark in 2004 by Chief Scientific Officer Steen Knudsen, Ph.D. It is pursuing a personalized medicine approach to build upon the success of its Drug Response Predictor (DRP®) companion diagnostic platform to advance oncology therapies, oriented towards combination therapies. The company offers a portfolio of three priority drug candidates, and plans to pursue a Phase Ib/II study in metastatic ovarian cancer starting in 4Q:22 with both stenoparib and dovitinib.

With executive leadership from CEO James G. Cullem, Allarity is taking a new approach to oncology drug development that relies on identification of cancer patients likely to respond to a drug based on an individual’s tumor cell transcriptome. This approach addresses some of the key drawbacks of conventional biomarker approaches, which fail to recognize the multifactorial drivers behind cancer and lack clinical validation. Allarity Therapeutics offers pipeline programs addressing significant markets in metastatic ovarian cancer (mOC), metastatic breast cancer (mBC) and, potentially, metastatic renal cell carcinoma (mRCC) ), among other indications. We will introduce you to Allarity’s DRP® companion diagnostic platform, its combination therapy approach, and the drivers for the company’s future success.

Drug Response Predictor (DRP®) Platform

The use of biomarkers predicting patient response is widespread. Biomarkers can be based on genetics, mutations, hormone receptor status, presence of enzymes, and tumor markers to name a few. Most of these approaches are one-dimensional, fail to recognize cancer as a mechanistically and biochemically diverse disease and lack clinical validation. To address this shortcoming, Allarity has developed its DRP® platform technology to identify cancer patients that are most likely to benefit from a specific drug.

Full story available on

Source link

Recommended For You

About the Author: News Center